Dr. Priya Nandakumar brings scientific and clinical insight to The Catalyst Brief’s coverage of biomedical research and healthcare innovation. Her work bridges experimental findings, clinical data, and industry strategy, helping readers interpret what new evidence means beyond the lab or trial setting. At The Catalyst Brief, Priya emphasizes translational relevance and long-term implications for patients and pipelines.
160 articlesMostly Regulatory & Policy and Biopharmaceutical Industry
Healthcare InvestmentTwo experts dissect the rise of the perimenopause movement, highlighting how an industry profiting from misinformation around hormones and supplements could be harming women's health rather than helping it. This analysis explores the complex landscape of perimenopause-related information, its commercial drivers, and the consequences for affected women.
Dr. Priya NandakumarMay 23, 2026
Healthcare InvestmentThe timely award of Medicaid funds to Florida hospitals represents a critical development with substantial implications for healthcare infrastructure and funding. This blog post explores the background, context, and potential impacts of this investment on Florida's healthcare landscape.
Dr. Priya NandakumarMay 21, 2026
Biopharmaceutical IndustryMore than half of biopharma professionals now accept underemployment, according to a BioSpace LinkedIn poll. This development reflects deeper industry dynamics and prompts discussion on career trajectories within biotech and pharmaceutical sectors.
Dr. Priya NandakumarMay 21, 2026
Biotech InnovationThe acquisition of Engage Bio highlights Eli Lilly's continued commitment to genetic medicine innovation by integrating novel delivery technologies aimed at enhancing therapeutic potential and patient outcomes.
Dr. Priya NandakumarMay 21, 2026
Biopharmaceutical IndustryDaiichi Sankyo has faced significant challenges in advancing its ADC portfolio over the past two years, limiting near-term commercial opportunities. Nonetheless, the company remains optimistic about upcoming clinical trial data that could elevate it into the elite ranks of cancer drug developers.
Dr. Priya NandakumarMay 20, 2026
Biotech InnovationBiotech firms, traditionally motors of scientific discovery and innovation, are increasingly constrained by market pressures stemming from Big Pharma's dominant business models. This growing tension threatens the sector's capacity to innovate. Structural reforms are essential to sustain and nurture biotech’s strategic innovation and maintain its role as a pioneer in biomedical advancements.
Dr. Priya NandakumarMay 19, 2026
Regulatory & PolicyAstraZeneca's recent FDA approval of Baxfendy brings forward a new class of hypertension drugs targeting aldosterone synthase. This approval not only offers hope to patients with high blood pressure but also represents AstraZeneca's strategic move amid looming patent expirations on its cardiometabolic portfolio.
Dr. Priya NandakumarMay 18, 2026
Regulatory & PolicyThe FDA is experiencing significant leadership upheaval, highlighted by the recent resignations within its highest ranks. The exit of interim CDER head Tracy Beth Høeg shortly after Commissioner Makary's resignation raises questions about the agency’s internal dynamics and the potential impact on its regulatory functions. This article explores the circumstances and implications surrounding these high-profile departures at the FDA.
Dr. Priya NandakumarMay 15, 2026
Regulatory & PolicyExcessive alcohol consumption continues to be a leading cause of preventable death in the United States. STAT's investigative work provides a comprehensive review of governmental and societal failures to tackle this pervasive epidemic, shedding light on the urgent need for actionable reform.
Dr. Priya NandakumarMay 14, 2026
Regulatory & PolicyIn response to persistent drug shortages and supply chain vulnerabilities, the European Union (E.U.) has agreed to a draft deal designed to bolster local production of essential medicines. This strategic initiative is intended to reduce reliance on global imports, thus enhancing the resilience and security of pharmaceutical supplies for member states. This article explores the context, mechanisms, and potential impacts of the E.U.'s policy framework on medicine availability and industry dynamics.
Dr. Priya NandakumarMay 12, 2026
Regulatory & PolicyThis lawsuit brings to light the increasing scrutiny on AI-driven chatbot platforms within the healthcare sector and raises important questions about safety, accountability, and the boundaries of artificial intelligence applications in medical practice.
Dr. Priya NandakumarMay 9, 2026
Biopharmaceutical IndustryEli Lilly is significantly expanding its manufacturing footprint in Indiana through a substantial $4.5 billion investment. This includes launching the Lilly Lebanon Advanced Therapies site, designed to accelerate the transition of cutting-edge genetic medicines from research phases into commercialization.
Dr. Priya NandakumarMay 8, 2026